Sept. 4, 2025 — Earlier today, Saol Therapeutics shared the U.S. Food and Drug Administration (FDA) has issued a Complete Response...
Read: UMDF Joins Other Mito Advocacy Groups to Issue Statement and Call to Action Regarding the FDA’s DCA DenialSignup to receive the UMDF newsletter in your email monthly at umdf.org/newsletter-signup. ...
Read: August 2025 Newsletter: No-Cost Genetic Testing, World Mito Week, FDA Action, Ask the Mito Doc Returns, and moreWe’re excited to unite with other mitochondrial disease-focused patient advocacy groups across the globe to spread awareness on World...
Read: Energize the Fight – World Mitochondrial Disease Week 2025Barth Syndrome Foundation, UMDF, and MitoAction leadership were recently notified by Stealth BioTherapeutics that FDA has refused their request...
Read: Advocacy Action: Ask FDA to Reconsider Elamipretide DecisionSignup to receive the UMDF newsletter in your email monthly at umdf.org/newsletter-signup. The Mito Fund Announces Investment in Pretzel...
Read: July 2025 Newsletter: Mito Fund Invests in POLG-Focused Company, MitoMed Grant & Award Winners, mitoSHARE Studies, and moreSignup to receive the UMDF newsletter in your email monthly at umdf.org/newsletter-signup. UMDF Launches New Mito Biorepository with...
Read: April 2025 Newsletter: New Mito Biorepository, MitoMed Highlights, Medicaid Survey Results, and MoreUMDF has partnered with the nonprofit COMBINEDBrain to develop a mitochondrial disease biorepository hosted on mitoSHARE, UMDF’s patient...
Read: UMDF Partners with COMBINEDBrain to Develop a Mitochondrial Disease Biorepository